ACADIA PHARMACEUTICALS INC. ACAD Income Statement

Acadia pharmaceuticals inc. (ACAD)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenues
Product sales, net
-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaborative revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	43	44	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenues
366,185	339,076	300,321	264,040	237,898	223,807	207,798	185,071	158,483	124,901	93,301	62,991	32,613	17,331	5,386	157	61	61	91	67	94	120	110	335	758	1,145	1,488	4,726	4,874	4,907	5,115	2,221	2,082	2,067	3,780	5,493	0	0	0
Operating expenses
Cost of product sales
11,193	11,344	11,147	12,570	13,174	12,377	12,009	10,305	8,967	9,077	7,467	5,858	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License fees and royalties
8,799	8,254	7,509	6,772	6,251	5,953	5,632	5,174	4,640	3,983	3,210	2,380	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
260,098	240,385	231,048	221,538	200,810	187,163	182,159	165,468	153,056	149,189	136,228	125,620	111,918	99,284	89,532	82,448	80,349	73,869	71,586	69,809	65,229	60,602	50,345	40,647	33,960	26,722	23,697	20,843	18,203	18,794	18,317	18,075	17,918	17,309	17,850	18,733	0	0	0
Selling, general and administrative
334,521	325,638	308,038	296,431	297,922	265,758	258,176	258,675	250,328	255,062	246,036	234,982	224,625	186,456	151,409	121,183	91,534	88,304	76,107	63,856	50,689	32,748	26,605	22,345	16,889	12,720	10,742	8,430	7,490	6,999	6,179	6,213	7,386	7,610	7,710	7,743	0	0	0
Total operating expenses
614,611	585,621	557,742	537,311	518,157	471,251	457,976	439,622	416,991	417,311	393,933	370,378	343,887	290,146	245,535	206,905	174,383	164,673	147,693	133,665	115,918	93,350	76,950	62,992	50,849	39,442	34,439	29,273	25,693	25,793	24,496	24,288	25,304	24,919	25,560	26,476	0	0	0
Loss from operations
-248,426	-246,545	-257,421	-273,271	-280,259	-247,444	-250,178	-254,551	-258,508	-292,410	-300,632	-307,387	-311,274	-272,815	-240,149	-206,748	-174,322	-164,612	-147,602	-133,598	-115,824	-93,230	-76,840	-62,657	-50,091	-38,297	-32,951	-24,547	-20,819	-20,886	-19,381	-22,067	-23,222	-22,852	-21,780	-20,983	0	0	0
Interest income, net
11,220	11,165	9,563	8,360	7,112	5,348	4,785	4,619	4,333	4,126	3,895	3,618	3,226	2,763	1,998	1,304	822	499	577	693	802	755	682	590	438	349	242	131	65	37	42	54	72	87	88	79	0	0	0
Other expense
2,265	997	-732	-1,232	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-237,477	-234,383	-247,225	-266,745	-275,216	-243,936	-247,360	-250,179	-254,175	-288,284	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense
-	876	490	1,130	984	1,256	1,211	1,502	1,681	1,119	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-237,978	-235,259	-247,715	-267,875	-276,200	-245,192	-248,571	-251,681	-255,856	-289,403	-299,228	-305,593	-309,474	-271,393	-238,481	-205,774	-173,830	-164,443	-147,025	-132,905	-115,022	-92,475	-76,158	-62,067	-49,653	-37,948	-32,709	-24,416	-20,754	-20,849	-19,339	-22,013	-23,150	-22,765	-21,692	-20,904	0	0	0
Net loss per common share, basic and diluted
-0.57	-0.34	-0.29	-0.38	-0.59	-0.49	-0.50	-0.51	-0.44	-0.56	-0.53	-0.55	-0.72	-0.65	-0.61	-0.63	-0.45	-0.45	-0.39	-0.39	-0.40	-0.29	-0.25	-0.22	-0.19	-0.13	-0.12	-0.11	-0.08	-0.12	-0.04	-0.10	-0.12	-0.10	-0.10	-0.12	-0.12	-0.11	-0.11
Weighted average common shares outstanding, basic and diluted
155,368	154,595	145,906	144,314	143,981	131,686	125,009	124,910	124,727	124,143	122,484	122,122	121,651	121,281	117,497	113,308	111,346	101,218	100,756	100,349	100,197	97,479	99,497	99,048	92,968	91,198	89,504	83,410	78,748	60,689	53,911	52,961	52,903	52,888	52,800	52,677	50,367	38,383	38,347
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-